McGwire gives up andro
St. Louis Cardinals home run star announces he stopped using the dietary supplement androstenedione four months ago. McGwire says he does not want to be portrayed as an endorser of the supplement. The supplement reached the height of publicity when McGwire announced he used andro to help recuperate from his training regimen. Subsequently, companies flooded the market with andro products. However, questions began to arise regarding the lack of clinical data supporting andro's steroidal effects and safety. In January, the ingredient was nominated for toxicity testing by the National Toxicology Program (1"The Tan Sheet" Jan. 4, p. 8)
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
A new chapter that will be published in the European Pharmacopoeia soon is expected to provide a comprehensive framework for the production and quality control of cell-based preparations. Meanwhile, an existing chapter has been revised to facilitate the implementation of rapid microbiological testing methods.
The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.
An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.